1107649-50-2

Upstream product

• 1107649-02-4 (1R,3S)-(-)-3-[1-(N-allyl-N-but-3-enoylamino)-1-methylethyl]cyclohexanecarboxylic acid methyl ester 
• 1107648-85-0 (1R,3S)-(-)-3-(1-allylamino-1-methylethyl)cyclohexanecarboxylic acid methyl ester 
• 1107648-80-5 (1R,3S)-(-)-3-(1-methyl-1-nitroethyl)cyclohexanecarboxylic acid methyl ester 
• 1107648-81-6 C₁₁H₂₁NO₂ 
• 1107649-01-3 (1R,3S)-3-[1-methyl-1-(6-oxo-3,6-dihydro-2H-pyridin-1-yl)-ethyl]-cyclohexane-carboxylic acid methyl ester 

Downstream Products

• 1107649-51-3 C₁₅H₂₅NO₃ 
• 1107649-49-9 (1R,3S)-3-[1-methyl-1-(2-oxo-piperidin-1-yl)-ethyl]-cyclohexanecarboxylic acid [(1S,2R)-1-benzyl-2-hydroxy-3-(3-isopropyl-benzylamino)-propyl]-amide 

Relevant academic research and scientific papers

Structure-based design and synthesis of novel P2/P3 modified, non-peptidic β-secretase (BACE-1) inhibitors

Starting from peptidomimetic BACE-1 inhibitors, the P2 amino acid including the P2/P3 peptide bond was replaced by a rigid 3-aminomethyl cyclohexane carboxylic acid. Co-crystallization revealed an unexpected binding mode with the P3/P4 amide bond placed into the S3 pocket resulting in a new hydrogen bond interaction pattern. Further optimization based on this structure resulted in highly potent BACE-1 inhibitors with selectivity over BACE-2 and cathepsin D.

SUBSTITUTED CYCLOHEXANECARBOXAMIDES USEFUL AS BACE INHIBITORS

The invention relates to novel amide compounds of the formula (I) in which all of the variables are as defined in the specification, in free form or in salt form, to their preparation, to their use as medicaments and to medicaments comprising them.